Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Transforming Evidence Generation to Support Health and Health Care Decisions.

Califf RM, Robb MA, Bindman AB, Briggs JP, Collins FS, Conway PH, Coster TS, Cunningham FE, De Lew N, DeSalvo KB, Dymek C, Dzau VJ, Fleurence RL, Frank RG, Gaziano JM, Kaufmann P, Lauer M, Marks PW, McGinnis JM, Richards C, Selby JV, Shulkin DJ, Shuren J, Slavitt AM, Smith SR, Washington BV, White PJ, Woodcock J, Woodson J, Sherman RE.

N Engl J Med. 2016 Dec 15;375(24):2395-2400. No abstract available.

2.

Neuropsychiatric events in varenicline and nicotine replacement patch users in the Military Health System.

Meyer TE, Taylor LG, Xie S, Graham DJ, Mosholder AD, Williams JR, Moeny D, Ouellet-Hellstrom RP, Coster TS.

Addiction. 2013 Jan;108(1):203-10. doi: 10.1111/j.1360-0443.2012.04024.x. Epub 2012 Oct 18.

PMID:
22812921
3.

Acetaminophen overdose in the Military Health System.

Taylor LG, Xie S, Meyer TE, Coster TS.

Pharmacoepidemiol Drug Saf. 2012 Apr;21(4):375-83. doi: 10.1002/pds.3206. Epub 2012 Feb 23.

PMID:
22362462
4.

A phase 1 study of a group B meningococcal native outer membrane vesicle vaccine made from a strain with deleted lpxL2 and synX and stable expression of opcA.

Keiser PB, Gibbs BT, Coster TS, Moran EE, Stoddard MB, Labrie JE 3rd, Schmiel DH, Pinto V, Chen P, Zollinger WD.

Vaccine. 2010 Oct 8;28(43):6970-6. doi: 10.1016/j.vaccine.2010.08.048. Epub 2010 Aug 21.

PMID:
20732470
5.

Immune response, ciprofloxacin activity, and gender differences after human experimental challenge by two strains of enterotoxigenic Escherichia coli.

Coster TS, Wolf MK, Hall ER, Cassels FJ, Taylor DN, Liu CT, Trespalacios FC, DeLorimier A, Angleberger DR, McQueen CE.

Infect Immun. 2007 Jan;75(1):252-9. Epub 2006 Oct 30.

6.

Two studies evaluating the safety and immunogenicity of a live, attenuated Shigella flexneri 2a vaccine (SC602) and excretion of vaccine organisms in North American volunteers.

Katz DE, Coster TS, Wolf MK, Trespalacios FC, Cohen D, Robins G, Hartman AB, Venkatesan MM, Taylor DN, Hale TL.

Infect Immun. 2004 Feb;72(2):923-30.

7.

Phase 1 studies of Walter Reed Army Institute of Research candidate attenuated dengue vaccines: selection of safe and immunogenic monovalent vaccines.

Kanesa-Thasan N, Edelman R, Tacket CO, Wasserman SS, Vaughn DW, Coster TS, Kim-Ahn GJ, Dubois DR, Putnak JR, King A, Summers PL, Innis BL, Eckels KH, Hoke CH Jr.

Am J Trop Med Hyg. 2003 Dec;69(6 Suppl):17-23. Erratum in: Am J Trop Med Hyg. 2004 Mar;70(3):336.

PMID:
14740951
8.

Combat medical informatics: present and future.

Hoyt RW, Reifman J, Coster TS, Buller MJ.

Proc AMIA Symp. 2002:335-9.

9.

Vaccination against shigellosis with attenuated Shigella flexneri 2a strain SC602.

Coster TS, Hoge CW, VanDeVerg LL, Hartman AB, Oaks EV, Venkatesan MM, Cohen D, Robin G, Fontaine-Thompson A, Sansonetti PJ, Hale TL.

Infect Immun. 1999 Jul;67(7):3437-43.

10.

Peru-15, an improved live attenuated oral vaccine candidate for Vibrio cholerae O1.

Kenner JR, Coster TS, Taylor DN, Trofa AF, Barrera-Oro M, Hyman T, Adams JM, Beattie DT, Killeen KP, Spriggs DR, et al.

J Infect Dis. 1995 Oct;172(4):1126-9.

PMID:
7561195
11.

Safety, immunogenicity, and efficacy of live attenuated Vibrio cholerae O139 vaccine prototype.

Coster TS, Killeen KP, Waldor MK, Beattie DT, Spriggs DR, Kenner JR, Trofa A, Sadoff JC, Mekalanos JJ, Taylor DN.

Lancet. 1995 Apr 15;345(8955):949-52.

PMID:
7715293
12.

Development of a live, oral, attenuated vaccine against El Tor cholera.

Taylor DN, Killeen KP, Hack DC, Kenner JR, Coster TS, Beattie DT, Ezzell J, Hyman T, Trofa A, Sjogren MH, et al.

J Infect Dis. 1994 Dec;170(6):1518-23.

PMID:
7995992
13.

Coronary artery fistula diagnosed by transesophageal echocardiography.

Prewitt KC, Smolin MR, Coster TS, Vernalis MN, Bunda M, Wortham DC.

Chest. 1994 Mar;105(3):959-61.

PMID:
8131580

Supplemental Content

Loading ...
Support Center